表紙
市場調查報告書
商品編碼
371021

白血球表面抗原 CD47:開發中產品分析

Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019

出版日期: | 出版商: Global Markets Direct | 英文 156 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供以白血球表面抗原為標的之治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊CD47。

簡介

  • 調查範圍

白血球表面抗原 CD47 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Aurigene Discovery Technologies Limited
  • Celgene Corporation
  • Trillium Therapeutics Inc.

藥物簡介

暫停中的計劃

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC2194TDB

Summary

According to the recently published report 'Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019'; Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) pipeline Target constitutes close to 53 molecules. Out of which approximately 51 molecules are developed by companies and remaining by the universities/institutes.

Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - CD47 (Cluster of Differentiation 47) or integrin associated protein (IAP) is a transmembrane protein encoded by the CD47 gene. It has a role in both cell adhesions by acting as an adhesion receptor for THBS1 on platelets, and in the modulation of integrins. It plays an important role in memory formation and synaptic plasticity in the hippocampus (By similarity). It acts as a receptor for SIRPA. Interaction with SIRPG mediates cell-cell adhesion, enhances superantigen-dependent T-cell-mediated proliferation and co-stimulates T-cell activation. It plays an important role in membrane transport and/or integrin dependent signal transduction. It prevents premature elimination of red blood cells.

The report 'Leukocyte Surface Antigen CD47 - Pipeline Review, H2 2019' outlays comprehensive information on the Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 10, 1, 28 and 9 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Infectious Disease and Metabolic Disorders which include indications Solid Tumor, Diffuse Large B-Cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Refractory Multiple Myeloma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Breast Cancer, Colorectal Cancer, Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Glioblastoma Multiforme (GBM), Ovarian Cancer, Pancreatic Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, B-Cell Non-Hodgkin Lymphoma, Blood Cancer, Cutaneous T-Cell Lymphoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Follicular Lymphoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Leukemia, Marginal Zone B-cell Lymphoma, Melanoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Triple-Negative Breast Cancer (TNBC), Bladder Cancer, Cerebral (Fatal) Malaria, Chronic Lymphocytic Leukemia (CLL), Colon Carcinoma, Diabetic Retinopathy, Gastric Cancer, Gastroesophageal (GE) Junction Carcinomas, Gastrointestinal Tract Cancer, Gliosarcoma, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, High-Grade Glioma, Leiomyosarcoma, Lung Cancer, Mantle Cell Lymphoma, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Mycosis Fungoides, Myeloproliferative Disorders, Neuroendocrine Tumors, Non-Small Cell Lung Carcinoma, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Peripheral T-Cell Lymphomas (PTCL), Sezary Syndrome, Thymic Carcinoma and Transitional Cell Cancer (Urothelial Cell Cancer).

Scope

  • The report provides a snapshot of the global therapeutic landscape for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
  • The report reviews Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Overview
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Companies Involved in Therapeutics Development
  • Abpro Corp
  • ALX Oncology Inc
  • Arch Oncology Inc
  • Aurigene Discovery Technologies Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Biocad
  • Bristol-Myers Squibb Co
  • EpicentRx Inc
  • Forty Seven Inc
  • GeneScience Pharmaceuticals Co Ltd
  • GigaGen Inc
  • Hummingbird Bioscience Pte Ltd
  • I-Mab Biopharma Co Ltd
  • ImmuneOncia Therapeutics LLC
  • ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
  • Innovent Biologics Inc
  • Jiangsu Hengrui Medicine Co Ltd
  • KAHR medical Ltd
  • LynkCell Inc
  • MesaGen LLC
  • NovImmune SA
  • Opsyon
  • Paradigm Shift Therapeutics LLC
  • Phanes Therapeutics Inc
  • PharmAbcine Inc
  • Shanghai Henlius Biotech Inc
  • Sorrento Therapeutics Inc
  • Surface Oncology Inc
  • Synthon Holdings BV
  • TOT Biopharm Co Ltd
  • Trillium Therapeutics Inc
  • Waterstone Hanxbio Pty Ltd
  • Leukocyte Surface Antigen CD47 (Antigenic Surface Determinant Protein OA3 or Integrin Associated Protein or Protein MER6 or CD47) - Drug Profiles
  • ABP-160 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ALX-148 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Appendix

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..3), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1)
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Abpro Corp, H2 2019
  • Pipeline by ALX Oncology Inc, H2 2019
  • Pipeline by Arch Oncology Inc, H2 2019
  • Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
  • Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Biocad, H2 2019
  • Pipeline by Bristol-Myers Squibb Co, H2 2019
  • Pipeline by EpicentRx Inc, H2 2019
  • Pipeline by Forty Seven Inc, H2 2019
  • Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2019
  • Pipeline by GigaGen Inc, H2 2019
  • Pipeline by Hummingbird Bioscience Pte Ltd, H2 2019
  • Pipeline by I-Mab Biopharma Co Ltd, H2 2019
  • Pipeline by ImmuneOncia Therapeutics LLC, H2 2019
  • Pipeline by ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd, H2 2019
  • Pipeline by Innovent Biologics Inc, H2 2019
  • Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019
  • Pipeline by KAHR medical Ltd, H2 2019
  • Pipeline by LynkCell Inc, H2 2019
  • Pipeline by MesaGen LLC, H2 2019
  • Pipeline by NovImmune SA, H2 2019
  • Pipeline by Opsyon, H2 2019
  • Pipeline by Paradigm Shift Therapeutics LLC, H2 2019
  • Pipeline by Phanes Therapeutics Inc, H2 2019
  • Pipeline by PharmAbcine Inc, H2 2019
  • Pipeline by Shanghai Henlius Biotech Inc, H2 2019
  • Pipeline by Sorrento Therapeutics Inc, H2 2019
  • Pipeline by Surface Oncology Inc, H2 2019
  • Pipeline by Synthon Holdings BV, H2 2019
  • Pipeline by TOT Biopharm Co Ltd, H2 2019
  • Pipeline by Trillium Therapeutics Inc, H2 2019
  • Pipeline by Waterstone Hanxbio Pty Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019